Opening up data at the European Medicines Agency

descriptionPublicationkeyboard_double_arrow_right Article 10 May 2011 Denmark English Publisher:BMJJournal:BMJ, volume 342, pages d2686-d2686 (issn: 0959-8138, eissn: 1468-5833,

Copyright policy )

Authors: Gøtzsche, Peter C; Jørgensen, Anders W;

doi: 10.1136/bmj.d2686

pmid: 21558364

Opening up data at the European Medicines Agency

- Summary
- Subjects
- Metrics

Abstract

Widespread selective reporting of research results means we don’t know the true benefits and harms of prescribed drugs. Peter Gotzsche and Anders Jorgensen describe their efforts to get access to unpublished trial reports from the European Medicines Agency

Country

Denmark

Related Organizations

Keywords

Europe, Clinical Trials as Topic, Information Storage and Retrieval, Registries

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	90
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%